Today
+0.90%
5 Days
+6.43%
1 Month
+14.51%
6 Months
+3.83%
Year to Date
+6.13%
1 Year
-6.73%
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
In contrast with the general assumption that Eli Lilly (LLY) is priced for perfection, the Q1 2025 numbers indicate the company's stock is in the nascent stages of a strategic turning point.
Though oncology remains the largest therapeutic area in the pharmaceutical industry, the weight management field has caught fire in the past few years. Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest...
.jpg)
WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.
May 12 (Reuters) - Eli Lilly LLY.N said on Sunday its drug Zepbound was superior to Novo Nordisk's NOVOb.CO Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
April 23 (Reuters) - Eli Lilly LLY.N said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines.odu...
April 17 (Reuters) - Eli Lilly's LLY.N experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.
